| P50 | author | Ivana Carey | Q57063795 |
| P2093 | author name string | D Vergani | |
| | G Mieli-Vergani | |
| | S Bansal | |
| | Y Zen | |
| | M Horner | |
| | M Bruce | |
| | L D'Antiga | |
| P2860 | cites work | Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa‐2b in HBeAg‐positive patients | Q51754356 |
| | Hepatitis B Virus Infection | Q54152887 |
| | Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir. | Q54373860 |
| | Comparison between quantitative hepatitis B surface antigen, hepatitis B e-antigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon-α-2b therapy in hepatitis B e-antigen-positive chronic hepatitis B | Q57002666 |
| | Sequential therapy with adefovir dipivoxil and pegylated Interferon Alfa-2a for HBeAg-negative patients | Q58034401 |
| | Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype | Q58376614 |
| | Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir | Q58376651 |
| | Serum HBsAg Decline During Long-term Potent Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B and Prediction of HBsAg Loss | Q58376653 |
| | Restored Function of HBV-Specific T Cells After Long-term Effective Therapy With Nucleos(t)ide Analogues | Q58802756 |
| | EASL clinical practice guidelines: Management of chronic hepatitis B virus infection | Q29615868 |
| | Hepatitis B virus infection--natural history and clinical consequences | Q29617961 |
| | Generation of covalently closed circular DNA of hepatitis B viruses via intracellular recycling is regulated in a virus specific manner. | Q33686965 |
| | Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy | Q34151071 |
| | Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B. | Q34252292 |
| | Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level | Q34481474 |
| | Immune and viral profile from tolerance to hepatitis B surface antigen clearance: a longitudinal study of vertically hepatitis B virus-infected children on combined therapy | Q34742036 |
| | The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection | Q36368397 |
| | Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors | Q37039155 |
| | Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report | Q37896235 |
| | Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B? | Q37969684 |
| | Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. | Q39021951 |
| | Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. | Q39329221 |
| | Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. | Q39540012 |
| | Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients | Q39736089 |
| | Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia | Q39894574 |
| | IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome | Q40679075 |
| | Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines: consensus of an expert panel on behalf of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. | Q42261635 |
| | Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes | Q42271127 |
| | Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. | Q42678962 |
| | Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. | Q42836672 |
| | Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients | Q42865759 |
| | Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline | Q42911213 |
| | On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients | Q43127390 |
| | Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B. | Q43299353 |
| | A randomized controlled trial of sequential pegylated interferon-α and telbivudine or vice versa for 48 weeks in hepatitis B e antigen-negative chronic hepatitis B. | Q43443038 |
| | Cure for immune-tolerant hepatitis B in children: is it an achievable target with sequential combo therapy with lamivudine and interferon? | Q43466658 |
| | Real-time PCR for detection and quantitation of hepatitis B virus DNA. | Q43728363 |
| | Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients | Q44425588 |
| | Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype | Q44520576 |
| | Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. | Q44929883 |
| | A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B. | Q45096224 |
| | Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers | Q45375655 |
| | Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. | Q45376159 |
| | Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. | Q45378210 |
| | Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. | Q45398888 |
| | Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: results of a long-term follow-up study in chronic hepatitis B patients. | Q45936266 |
| | Combined lamivudine/interferon-alpha treatment in "immunotolerant" children perinatally infected with hepatitis B: a pilot study | Q46955729 |
| | Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum. | Q51609113 |
| P433 | issue | 4 | |
| P304 | page(s) | 441-452 | |
| P577 | publication date | 2014-10-03 | |
| P1433 | published in | Journal of Viral Hepatitis | Q15749962 |
| P1476 | title | HBsAg plasma level kinetics: a new role for an old marker as a therapy response predictor in vertically infected children on combination therapy | |
| P478 | volume | 22 | |